About Drovelis®
Drovelis® is Richter's brand name for a novel oral contraceptive product composed of 15 mg estetrol (E4), its unique native estrogen acting selectively in tissues and 3 mg drospirenone. The E4 Freedom studies were open-label single arm trials and they were aimed to assess the safety and efficacy of the product in over 1,550 participants in Europe/Russia and approximately 2,150 participants in the US/Canada, over a period of 13 cycles.
For further information:
Investors: Katalin Ördög: +36 1 431 5680
Media: Zsuzsa Beke: +36 1 431 4888
Attachments
- Original document
- Permalink
Disclaimer
Gedeon Richter plc published this content on 20 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2021 15:06:02 UTC.